Novavax (NVAX) Receivables - Other (2011 - 2026)

Novavax's Receivables - Other history runs 13 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Receivables - Other fell 31.15% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 31.15% decrease from a year earlier, with the FY2025 full-year figure at $10.8 million, up 100.0% from the prior year.
• Receivables - Other fell to $4.2 million in Q1 2026 per NVAX's latest filing, from $10.8 million in the prior quarter.
• Across five years, Receivables - Other topped out at $68.0 million in Q3 2022 and bottomed at $200000.0 in Q1 2024.
• The 5-year median for Receivables - Other is $10.8 million (2023), against an average of $23.0 million.
• Across the five-year window, Receivables - Other slumped 99.53% in 2024 and jumped 2950.0% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $28.6 million in 2022, then plunged by 62.24% to $10.8 million in 2023, then sank by 50.0% to $5.4 million in 2024, then soared by 100.0% to $10.8 million in 2025, then plunged by 61.11% to $4.2 million in 2026.
• Per Business Quant, the three latest NVAX Receivables - Other figures stand at $4.2 million (Q1 2026), $10.8 million (Q4 2025), and $5.2 million (Q3 2025).